FULC

Fulcrum Therapeutics Inc

$14.03

chg

-0.71 (-4.82%)

quotes and stock data may be delayed 15 minutes

52 wk low

6.85

52 wk hi

33.1

Cash

$240.3M

Burn Rate (Qtr)

$20.8M

Mkt Cap

$568.9m

Avg Volume

595,014

*cash/burn updated:

Q3 '21

Drug Pipeline

Click on drug name or indication to see upcoming trial info, prior data, and more general information.

No drug found

We have found any drug for this company yet

Drug | Disease (links)

Stage (next event)

Catalyst Date

Losmapimod (p38 inhibitor)

Muscle degeneration, Muscle weakness

Phase 2b

Update

Exp Date

A free account is required to see the catalyst dates, notes, and more!

FTX-6058 (EED inhibitor)

Sickle cell disease, COVID-19

Phase 1b

Initiation

Exp Date

A free account is required to see the catalyst dates, notes, and more!

Losmapimod (p38 inhibitor)

COVID-19

Failed

Discontinued

Exp Date

A free account is required to see the catalyst dates, notes, and more!

Loading Catalysts...

search in progress

Pipeline powered by

FULC

BPIQ_Logo_RGB-01.jpg

Company Profile

Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s proprietary product engine identifies drug targets which can modulate gene expression to treat the known root cause of gene mis-expression.

Recent Posts

See what the community is saying - click to see full post.